Entering text into the input field will update the search result below

NCI-led study in treatment-resistant NHL builds on Kite Pharma's successful ZUMA-1 study of axicabtagene ciloleucel by showing durability of response

Mar. 15, 2017 9:15 AM ETKite Pharma (KITE) StockBy: Douglas W. House, SA News Editor14 Comments
  • Kite Pharma (NASDAQ:KITE) is up a fraction premarket on light volume in response to the results from a National Cancer Institute (NCI)-led research study assessing a single dose of anti-CD19 CAR T-cell therapy in 22 patients with refractory/relapsed non-Hodgkin lymphoma (NHL). The data were just published in the Journal of Clinical Oncology.
  • Objective response (OR) rate was 73% (n=16/22) and the complete response (CR) rate was 55% (n=12/22). In patients with aggressive B-cell NHL, OR and CR were 68% and 47%, respectively. Duration of responses ranged from more than seven months to more than 24 months, with 11 of 12 (92%) complete responders ongoing.
  • Reversible grade 3 (severe) or grade 4 (life-threatening) neurotoxicity was observed in 55% (n=12/22) of treated patients.
  • The results build on the successful Phase 3 ZUMA-1 trial of axicabtagene ciloleucel that showed 36% CR and extended survival.
  • Previously: Kite's lead product candidate successful in late-stage blood cancer study (Feb. 28)

Recommended For You

Related Stocks

SymbolLast Price% Chg
KITE--
Kite Pharma